Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silymarin for nonalcoholic hepatic steatosis
2005-002966-12Phase 2Active
- Sponsor
- TrasTec
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of silymarin in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by TrasTec. Started Nov 2005; status: active.
02
Drugs
silymarin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2005-002966-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002966-12.